

SamanTree Medical announces the strengthening of its management team to lead the new development phase of the company

Lausanne - Switzerland – December 10th 2021 – SamanTree Medical, committed to improving cancer surgery outcomes, is building-out its senior leadership team by welcoming Dr Oleg Svanidze as Chief Medical Officer and Mr Cédric Trabucatti as Vice President Sales & Marketing.

“I’m looking forward to working with Cedric and Oleg as this is a very exciting time for them to join the company. We are currently at pivotal stages in both our clinical roadmap and commercialization phase, and their extensive experience in the medical industry will be crucial to prepare for scaling up”, said Bastien Rachet, Co-founder and CEO of SamanTree Medical.

An exciting clinical roadmap ahead

Following promising insertions of the Histolog® Scanner into the operating rooms of leading centers in Europe, SamanTree Medical is ready to enter into a new phase on its clinical roadmap.

“The coming year is crucial, with several publications in progress and pivotal trials in various clinical applications planned, not to mention the many opportunities abroad. I am excited to join the adventure and participate in the intense year ahead”, said Dr Oleg Svanidze.



Dr. Oleg Svanidze has over 20 years of experience in the medical device industry with a background in clinical cardiac surgery and a successful track record in all aspects of clinical/medical affairs, R&D, and business development. He joined SamanTree Medical from Newronika, where he was serving as a Chief Medical Officer. Prior to Newronika, Dr. Svanidze held executive positions at several medical device companies, including Xeltis, Allergan Medical, Arbor Surgical Technologies, 3F Therapeutics (now Medtronic), Computer Motion (now Intuitive Surgical), and HeartPort (now Edwards Lifesciences). Oleg is a co-author of many scientific publications and holds several patents in the fields of minimally invasive heart valves and medical robotics.

Many opportunities with centers willing to solve their unmet medical need

In addition, SamanTree Medical continues to extend its user base, with exciting insertions of the Histolog® Scanner in clinical routines to come in various applications.

“SamanTree Medical's approach is a breakthrough in fresh tissue imaging at the point of care, which inspired me to take on this new challenge and be part of this success story”, commented Cédric Trabucatti.



SamanTree
Medical SA



Mr. Cédric Trabucatti has over 15 years as Sales Director EMEA for medical device companies. During his most recent experience at Varian, Angiodynamics and Mauna Kea technologies , he led the sales of innovative equipment in oncology. His career path has given him the ability to launch products with high added value and strengthen his ability to develop new business opportunities. Cedric holds a master degree in Science and also in management.

About SamanTree Medical

SamanTree Medical has developed a breakthrough medical imaging modality that enables new medical procedures with the will to improve cancer treatment. The Histolog® Scanner has been a CE mark product since 2016 for high resolution imaging of the surface of fresh tissue. It is based on a novel ultra-fast confocal microscopy technology invented in EPFL in 2010. This innovation finds its application along the patient journey, from biopsy taking to surgical diagnostics.

www.samantree.com / Contact : info@samantree.com

Histolog®
Scanner

The Histolog® Scanner v2 (CE mark in 2018) provides a breakthrough innovation for checking complete tumor removal during surgery. This new imaging modality offers surgeons and pathologists the real-time ability to identify cancerous tissues and react upon it. Its innovative design makes it highly practical for quick assessment of fresh specimens and the clinician is one touch-on-the-screen away from visualizing cancerous cells immediately. It covers a broad range of surgical and diagnostic applications in oncology.